-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Chongqing Yaoyou Pharmaceutical's acarbose tablets and China Resources Secco Pharmaceutical's acarbose tablets were approved for production on the same day as Class 4 generics, which are regarded as over-evaluation
.
According to data from Minet.
com, in 2020, the total sales of acarbose tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 4 billion yuan, and Bayer has the largest market share
.
On March 18, 2022, the drug approval certificate is pending information release.
Acarbose tablets are suitable for the treatment of type 2 diabetes, and also suitable for reducing postprandial blood sugar in patients with impaired glucose tolerance
.
The product was developed by Bayer and was first launched in Germany in 1990
.
According to data from Minet.
com, in 2020, the total sales of acarbose tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacy terminals will exceed 4 billion yuan.
Bayer has the largest market share
.
Source of review of Acarbose Tablets: Consistency Evaluation Database of Minet Thirteen companies, including Xiangjiang Pharmaceutical and Lepu Pharmaceutical, were reviewed
.
In addition, 5 companies including Beijing Jingfeng Pharmaceutical Group, Zhejiang Haixiang Pharmaceutical, and Guizhou Tianan Pharmaceutical have submitted their listing applications for review and approval
.
Data sources: State Food and Drug Administration official website, Minet database Note: Minet China's urban physical pharmacy terminal competition pattern database covers 297 cities and above in the country (excluding county and rural physical pharmacies), and continuous Monitored enlarged version of the city's physical pharmacy database
.
The above sales are calculated based on the average retail price of the product in the terminal
.
.
According to data from Minet.
com, in 2020, the total sales of acarbose tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 4 billion yuan, and Bayer has the largest market share
.
On March 18, 2022, the drug approval certificate is pending information release.
Acarbose tablets are suitable for the treatment of type 2 diabetes, and also suitable for reducing postprandial blood sugar in patients with impaired glucose tolerance
.
The product was developed by Bayer and was first launched in Germany in 1990
.
According to data from Minet.
com, in 2020, the total sales of acarbose tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacy terminals will exceed 4 billion yuan.
Bayer has the largest market share
.
Source of review of Acarbose Tablets: Consistency Evaluation Database of Minet Thirteen companies, including Xiangjiang Pharmaceutical and Lepu Pharmaceutical, were reviewed
.
In addition, 5 companies including Beijing Jingfeng Pharmaceutical Group, Zhejiang Haixiang Pharmaceutical, and Guizhou Tianan Pharmaceutical have submitted their listing applications for review and approval
.
Data sources: State Food and Drug Administration official website, Minet database Note: Minet China's urban physical pharmacy terminal competition pattern database covers 297 cities and above in the country (excluding county and rural physical pharmacies), and continuous Monitored enlarged version of the city's physical pharmacy database
.
The above sales are calculated based on the average retail price of the product in the terminal
.
